Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Parkinson's HelpLine


Learn More

Educational Materials


Do you want to know more about Parkinson's? PDF's materials provide information about symptoms, medications, resources & more.

Order Free Materials Today

New Prospects for Slowing the Progression of Parkinson's Disease

Hosted by PDF
New York, NY
Thursday, March 19, 2009
2:00 – 4:00 PM

This 'mini-webcast' includes Dr. Henchcliffe's presentation on basic updates in Parkinson's research.  The entire webcast is two and a half hours long, though Dr. Henchcliffe's discussion is approximately one hour.

View Webcast


Speaker Biography

Claire Henchcliffe, M.D., D.Phil., is the Director of the Parkinson’s and Movement Disorders Institute at Weill Cornell Medical Center in New York City, where she serves as both a researcher and clinician.

Her current research focuses on biomarker development in Parkinson’s disease (PD).  She and her colleagues are studying two avenues for biomarking - including magnetic resonance spectroscopy (MRS) and a blood test utilizing metobolomics.  She is also involved with clinical research, particularly with the trial for Coenzyme Q10 (CoQ10), funded by the National Institute of Neurological Disorders and Stroke. 

Dr. Henchcliffe is the founder of a PD support group at Weill Cornell and serves as Co-Chair of the Working Group on Biomarkers of the Parkinson Study Group (PSG).  She also mentors medical students and residents and frequently lectures and writes about PD.

Dr. Henchcliffe received her medical degree from Columbia University, College of Physicians and Surgeons in New York City and her doctorate from the University of Oxford, United Kingdom. She completed both her internship and residency in Neurology and a fellowship in Movement Disorders under Stanley Fahn, M.D., at Columbia Presbyterian Medical Center's Neurological Institute.

Dr. Henchcliffe’s work is supported as part of PDF’s Center Grant to Weill Cornell Medical Center.  For FY 2008, PDF’s grant of $100,000 provided partial funding to Dr. Henchcliffe’s research.